Login

u/stockratic

r/biotech_stocks r/Pennystock r/pennystocks r/CAPR_Stock r/10xPennyStocks
OSR Health (OSRH) - refused to reverse split - the CEO is an excellent communicator to shareholders - company is mispriced/undervalued and this setup has strong potential!
▲ 7 r/10xPennyStocks+2 crossposts

OSR Health (OSRH) - refused to reverse split - the CEO is an excellent communicator to shareholders - company is mispriced/undervalued and this setup has strong potential!

I think this one is a GREAT opportunity for a multiples return! I have 70,000 shares.

  • 8/13/2026: SP ~ $0.26 to $0.28 / ~ MC $10M
    • Underpriced/mispriced in a big way!
    • Emerging Growth Research: 12-mth Price Target - $10.00
  • It's a holding company, currently with 3 subsidiaries/product lines.
    • Vaximm's VMX01 drug: encouraging Phase 1 trial data in pancreatic cancer
      • P2 trial completed in recurrent gioblastoma (GBM) in collaboration with Merck, Darmstadt, Germany and Pfizer.
      • Submitting GBM trial results for peer review.
      • FDA and European Commission Orphan designation.
    • Darnatein: platform that uses AI to generate "hybrid" endogenous proteins.
      • DRT 101: super-agonist for joint cartilage regeneration.
    • Woori IO: non-invasive glucose monitoring device.
      • Seeking Big Tech partnerships in the wearables market.

Current Status:

  • Facing a delisting letter on or about the Aug 31 deadline (2nd 180-day period ends).
  • CEO said the Board decided not to reverse split.
  • Instead, they put in place a CVR shareholder loyalty program for shareholders of record today, 8/14. Check this out: OSR Health. It gives a great idea of where the CEO believes their share price should/could be and the time frames.
  • The CEO is an excellent communicator to shareholders (refer to the 3 or 4 very recent shareholder letters, one was this week). Shareholders want companies with CEO's that operate this way to succeed.
  • Signed an $815M milestone-based licensing agreement for VMX01, with BCM Europe!
    • Includes a $15M put that can be exercised in Oct 2026 at $10 per share as part of that contract (negligible dilution).
  • The CEO sent the below Aug 11 shareholder letter that states the have had two inquiries for out-licensing of their products: one is preliminary term sheet negotiation phase and the other is early stage.
  • The CEO stated that he is also trying to move up the October $15M put date.

IMO, here's how things should unfold going forward:

  • On or about Aug 18, the "practical deadline," OSRH will receive a NASDAQ delisting determination letter.
  • OSRH will file a request for hearing. They have 7 calendar days to do so.
  • By Aug 25, NASDAQ will receive the request.
    • Per AI, upon NASDAQ receiving the request, it automatically STAYS the delisting.
  • By Aug 28 (within 3 days) NASDAQ will reply with an acknowledgement letter granting the request.
  • By Sep 9 to Sep 29 (within 10 to 20 days after the acknowledgement letter) OSRH will receive notification of a hearing date, which is typically set 30 to 45 days from the date of the hearing request.
  • Between Sep 24 and Oct 9, the hearing should take place.

NASDAQ delisting hearing panels love to see a plan with real catalysts. Per AI, the typical length of extension they grant is 30 to 45 days for the company to become compliant.

IMO, OSRH should be valued far above $1 right now, solely based on its VMX01 P2 results. It's a hidden gem with great potential!

There are many biotechs in P1/P2 (oncology and cardiology) that have MCs between $50M and even up to $150M and even some higher.

  • In my opinion, OSRH should be trading at a MC of between $50M to $100M RIGHT NOW -- a 5x to 10x opportunity if priced competitively. A couple of examples with a quick search:
    • Cardiff Oncology (CRDF) - P2 completed - $76M MC - PLK1 inhibitor
    • Immutep (IMMP) - P2 completed - $58M MC - LAG-3 immunotherapy

I found another biotech hidden gem that has unbelievable potential (P3 completed) and is greatly underpriced. I hope to make a post about it soon.

u/stockratic — 6 days ago
▲ 1 r/Pennystock

NRx Pharmaceuticals (NRXP) - Imminent Catalyst - 8-K dropped today (follow-up to yesterday's post - I encourage you to check it out). The stock is up nicely this morning, as a result! One of my favorite companies to hold. This company is a winner ... now ... and longer term.

Key Points:

  • Read the words I bolded in the 8-K below. In my opinion, it was completely unnecessary for the FDA reviewer to make this citation. All the excellent documentation/evidence was already provided in the ANDA submission. To pass this hurdle all that is needed is for the manufacturers of the "vial tip" to sign a certification. C'mon ... really!
  • After KETAFREE is approved, ask yourself why any company would continue to purchase ketamine containing the BZT toxin.
  • Remember from yesterday's post, they raised substantial cash very recently and are very prepared for manufacturing the drug. This is huge!
  • As stated in the 8-K, the FDA will review the manufacturer certification sign-offs "in the shortest possible review time frame" due to the ketamine shortage.
  • Imminent Catalysts (in either order):
    • KETAFREE approval
    • NRX-100 NDA submission (a different formulation of preservative-free IV ketamine than KETAFREE, for psychiatric use)

I have loved this company and its mission since I discovered it. I truly want them to succeed. It has been wonderful to observe their progress and listen to their earnings calls. Their goal is to destigmatize depression of any type (esp. severe) and have a nationwide network of clinics to treat anyone in need (think...military, first responders, victims of assault, and more). They are after treatments that have an immediate positive transformative effect.

8-K: nrxp20260806_8k.htm

"As previously disclosed, NRx Pharmaceuticals Inc. (the “Company”) filed an Abbreviated New Drug Application (“ANDA”) for preservative free ketamine in September 2025. The FDA advised the Company on July 30, 2026 of a final determination on first-round review that there were no major deficiencies related to the drug components of the product. The FDA did ask the company to update the label of the product to reflect a labeling change filed by the manufacturer of the Reference Listed Drug (Ketalar®) and identified a major deficiency related to the twist-off cap of the product’s luer lock vial, where an FDA reviewer expressed concern that the vial tip had the potential to deform in clinical use. The FDA sought confirmation that this could not pose a risk to patient safety. The classification as major is required because the matter affects the container closure.

 

Management advised the FDA that the luer lock vial has been used in three previously-approved ANDA products and 11.9 million doses of those products have been shipped in the past 12 months without complaints, returns, or recalls. The ANDA contained testing information on 3,500 vials randomly selected from the first 7 manufacturing batches in which the proper function of the luer lock tip was assessed and no defects were observed in any tested vial. The Company additionally provided verification data from an independent reference laboratory documenting that the torque (measured in Newton-Centimeters) required to open the vial was within the design specifications of the product and the three currently-approved ANDA products.

 

The FDA granted the Company a clarification meeting that was held on August 6, 2026 to identify the exact information that the Company will be required to provide to address the FDA’s concern about the proper function of the luer lock vial tip. The FDA requested that the company submit certifications from its manufacturer that the preservative-free ketamine ANDA product is manufactured on the same manufacturing lines with the same machinery, plastics, and other characteristics as the three approved ANDA products already in commercial distribution. This information was included in the ANDA as submitted and will now be supplied to the FDA as signed certifications from the Company’s manufacturers.

 

Based on the meeting, the FDA committed to immediately reinitiate review of the ANDA in order to resolve this single identified major deficiency and committed to completing the review in the shortest-possible review cycle. The meeting was attended both by leadership of the Office of Generic Drugs and by Senior Leadership of the FDA Center for Drug Evaluation and Research (CDER). FDA recognized that ketamine is a strategic drug that appears on the current FDA drug shortage list.

 

NRx management views the completion of a first-round ANDA review with no drug-related major deficiencies as a positive outcome, given that only 14% - 18% of ANDAs are estimated to achieve approval on first-round review. Although no assurances can be given on regulatory determinations, management is optimistic that the identified concern related to packaging will be resolved in a timely manner, consistent with first commercial sales in 2026, given that FDA has recognized the current drug shortage and lack of U.S.-based supply of ketamine and has committed to completing the review in the shortest possible review time frame. HHS leadership has identified ketamine as a strategic drug, as have other agencies and departments of the Federal Government."

reddit.com
u/stockratic — 13 days ago
▲ 9 r/pennystocks

NRx Pharmaceuticals (NRXP) - Imminent Catalyst - 8-K dropped today (follow-up to yesterday's post - I encourage you to check it out). The stock is up nicely this morning, as a result! One of my favorite companies to hold. This company is a winner ... now ... and longer term.

Key Points:

  • Read the words I bolded in the 8-K below. In my opinion, it was completely unnecessary for the FDA reviewer to make this citation. All the excellent documentation/evidence was already provided in the ANDA submission. To pass this hurdle all that is needed is for the manufacturers of the "vial tip" to sign a certification. C'mon ... really!
  • After KETAFREE is approved, ask yourself why any company would continue to purchase ketamine containing the BZT toxin.
  • Remember from yesterday's post, they raised substantial cash very recently and are very prepared for manufacturing the drug. This is huge!
  • As stated in the 8-K, the FDA will review the manufacturer certification sign-offs "in the shortest possible review time frame" due to the ketamine shortage.
  • Imminent Catalysts (in either order):
    • KETAFREE approval
    • NRX-100 NDA submission (a different formulation of preservative-free IV ketamine than KETAFREE, for psychiatric use)

I have loved this company and its mission since I discovered it. I truly want them to succeed. It has been wonderful to observe their progress and listen to their earnings calls. Their goal is to destigmatize depression of any type (esp. severe) and have a nationwide network of clinics to treat anyone in need (think...military, first responders, victims of assault, and more). They are after treatments that have an immediate positive transformative effect.

8-K: nrxp20260806_8k.htm

"As previously disclosed, NRx Pharmaceuticals Inc. (the “Company”) filed an Abbreviated New Drug Application (“ANDA”) for preservative free ketamine in September 2025. The FDA advised the Company on July 30, 2026 of a final determination on first-round review that there were no major deficiencies related to the drug components of the product. The FDA did ask the company to update the label of the product to reflect a labeling change filed by the manufacturer of the Reference Listed Drug (Ketalar®) and identified a major deficiency related to the twist-off cap of the product’s luer lock vial, where an FDA reviewer expressed concern that the vial tip had the potential to deform in clinical use. The FDA sought confirmation that this could not pose a risk to patient safety. The classification as major is required because the matter affects the container closure.

 

Management advised the FDA that the luer lock vial has been used in three previously-approved ANDA products and 11.9 million doses of those products have been shipped in the past 12 months without complaints, returns, or recalls. The ANDA contained testing information on 3,500 vials randomly selected from the first 7 manufacturing batches in which the proper function of the luer lock tip was assessed and no defects were observed in any tested vial. The Company additionally provided verification data from an independent reference laboratory documenting that the torque (measured in Newton-Centimeters) required to open the vial was within the design specifications of the product and the three currently-approved ANDA products.

 

The FDA granted the Company a clarification meeting that was held on August 6, 2026 to identify the exact information that the Company will be required to provide to address the FDA’s concern about the proper function of the luer lock vial tip. The FDA requested that the company submit certifications from its manufacturer that the preservative-free ketamine ANDA product is manufactured on the same manufacturing lines with the same machinery, plastics, and other characteristics as the three approved ANDA products already in commercial distribution. This information was included in the ANDA as submitted and will now be supplied to the FDA as signed certifications from the Company’s manufacturers.

 

Based on the meeting, the FDA committed to immediately reinitiate review of the ANDA in order to resolve this single identified major deficiency and committed to completing the review in the shortest-possible review cycle. The meeting was attended both by leadership of the Office of Generic Drugs and by Senior Leadership of the FDA Center for Drug Evaluation and Research (CDER). FDA recognized that ketamine is a strategic drug that appears on the current FDA drug shortage list.

 

NRx management views the completion of a first-round ANDA review with no drug-related major deficiencies as a positive outcome, given that only 14% - 18% of ANDAs are estimated to achieve approval on first-round review. Although no assurances can be given on regulatory determinations, management is optimistic that the identified concern related to packaging will be resolved in a timely manner, consistent with first commercial sales in 2026, given that FDA has recognized the current drug shortage and lack of U.S.-based supply of ketamine and has committed to completing the review in the shortest possible review time frame. HHS leadership has identified ketamine as a strategic drug, as have other agencies and departments of the Federal Government."

reddit.com
u/stockratic — 13 days ago
▲ 5 r/biotech_stocks

NRx Pharmaceuticals (NRXP) - Imminent Catalyst - 8-K dropped today (follow-up to yesterday's post - I encourage you to check it out). The stock is up 20% this morning! One of my favorite companies to hold. This company is a winner ... now ... and longer term.

Key Points:

  • Read the words I bolded in the 8-K below. In my opinion, it was completely unnecessary for the FDA reviewer to make this citation. All the excellent documentation/evidence was already provided in the ANDA submission. To pass this hurdle all that is needed is for the manufacturers of the "vial tip" to sign a certification. C'mon ... really!
  • After KETAFREE is approved, ask yourself why any company would continue to purchase ketamine containing the BZT toxin.
  • Remember from yesterday's post, they raised substantial cash very recently and are very prepared for manufacturing the drug. This is huge!
  • As stated in the 8-K, the FDA will review the manufacturer certification sign-offs "in the shortest possible review time frame" due to the ketamine shortage.
  • Imminent Catalysts (in either order):
    • KETAFREE approval
    • NRX-100 NDA submission (a different formulation of preservative-free IV ketamine than KETAFREE, for psychiatric use)

I have loved this company and its mission since I discovered it. I truly want them to succeed. It has been wonderful to observe their progress and listen to their earnings calls. Their goal is to destigmatize depression of any type (esp. severe) and have a nationwide network of clinics to treat anyone in need (think...military, first responders, victims of assault, and more). They are after treatments that have an immediate positive transformative effect.

8-K: nrxp20260806_8k.htm

"As previously disclosed, NRx Pharmaceuticals Inc. (the “Company”) filed an Abbreviated New Drug Application (“ANDA”) for preservative free ketamine in September 2025. The FDA advised the Company on July 30, 2026 of a final determination on first-round review that there were no major deficiencies related to the drug components of the product. The FDA did ask the company to update the label of the product to reflect a labeling change filed by the manufacturer of the Reference Listed Drug (Ketalar®) and identified a major deficiency related to the twist-off cap of the product’s luer lock vial, where an FDA reviewer expressed concern that the vial tip had the potential to deform in clinical use. The FDA sought confirmation that this could not pose a risk to patient safety. The classification as major is required because the matter affects the container closure.

 

Management advised the FDA that the luer lock vial has been used in three previously-approved ANDA products and 11.9 million doses of those products have been shipped in the past 12 months without complaints, returns, or recalls. The ANDA contained testing information on 3,500 vials randomly selected from the first 7 manufacturing batches in which the proper function of the luer lock tip was assessed and no defects were observed in any tested vial. The Company additionally provided verification data from an independent reference laboratory documenting that the torque (measured in Newton-Centimeters) required to open the vial was within the design specifications of the product and the three currently-approved ANDA products.

 

The FDA granted the Company a clarification meeting that was held on August 6, 2026 to identify the exact information that the Company will be required to provide to address the FDA’s concern about the proper function of the luer lock vial tip. The FDA requested that the company submit certifications from its manufacturer that the preservative-free ketamine ANDA product is manufactured on the same manufacturing lines with the same machinery, plastics, and other characteristics as the three approved ANDA products already in commercial distribution. This information was included in the ANDA as submitted and will now be supplied to the FDA as signed certifications from the Company’s manufacturers.

 

Based on the meeting, the FDA committed to immediately reinitiate review of the ANDA in order to resolve this single identified major deficiency and committed to completing the review in the shortest-possible review cycle. The meeting was attended both by leadership of the Office of Generic Drugs and by Senior Leadership of the FDA Center for Drug Evaluation and Research (CDER). FDA recognized that ketamine is a strategic drug that appears on the current FDA drug shortage list.

 

NRx management views the completion of a first-round ANDA review with no drug-related major deficiencies as a positive outcome, given that only 14% - 18% of ANDAs are estimated to achieve approval on first-round review. Although no assurances can be given on regulatory determinations, management is optimistic that the identified concern related to packaging will be resolved in a timely manner, consistent with first commercial sales in 2026, given that FDA has recognized the current drug shortage and lack of U.S.-based supply of ketamine and has committed to completing the review in the shortest possible review time frame. HHS leadership has identified ketamine as a strategic drug, as have other agencies and departments of the Federal Government."

reddit.com
u/stockratic — 13 days ago
▲ 35 r/10xPennyStocks+3 crossposts

NRX Pharmaceuticals (NRXP) - Imminent Catalyst and other statuses! This company is on the move and gaining traction. Price targets are multiples of the current share price.

NRXP - Severe Depression, PTSD

FINALLY, IT's TIME! They are at the finish line for one of three drugs!

Been following this company for well over a year. Posted about them a year ago. Major progress since then.

  • IMMINENT FDA decision:
    • GDUFA (generic drug) date of 7/29/2026 has passed with no word yet from the FDA on a decision for the ANDA submission for KETAFREE, which is a preservative‑free IV ketamine formulation for the following indications: sedation/anesthesia and analgesia (pain management).
      • Does NOT contain the known toxic preservative, benzethonium chloride (BZT), which is used in current ketamine formulations found in multi-dose vials.
    • HOWEVER, on 7/31 there was a CEO update on NRXP's website, which is HIGHLY encouraging for a potential approval: https://www.nrxpharma.com/management-answers-to-shareholder-questions/
      • "July 31, 2026
    • "Investors have inquired about the status of NRx’s ANDA application for preservative-free ketamine. The company has been advised that there are no Major Deficiencies related to the drug product, API, formulation, labeling, and related matters. The Company has been engaged with FDA in review of the packaging, which includes an innovative luer lock vial already used in allowing for needle-free withdrawal of the medication, unlike traditional glass vials.  The FDA has advised the company to anticipate a determination on the packaging today."
    • Other relevant facts:
      • Raised $7M in post-Q1 stock sales
      • Raised $22.3M at $3.50/share, in an underwritten public offering (June 4, 2026)
      • Manufacturing of KETAFREE is in the U.S.
      • Per the CEO: can produce 1M units per week and will have 1M units warehoused at launch
      • Filed a Citizen Petition, asking the FDA to require the elimination of benzethonium chloride (BZT) — a preservative still present in most multi‑dose ketamine vials but not recognized as safe by FDA
  • NRX-100 (Preservative-free IV Ketamine formulation)
    • For the following indications:
      • Suicidal ideation in major depressive disorder
      • Suicidal ideation in bipolar depression
      • Treatment‑resistant depression with suicidality (broader indication proposed)
    • NDA (Fast Track) submission in final stages.
      • Target Date: June 30, 2026.
      • Date has passed, so presuming submission may be imminent
  • NRX-101
    • Fixed‑dose combination of:
      • D‑cycloserine (DCS) — an NMDA receptor modulator
      • Lurasidone — a 5‑HT2A antagonist used in bipolar depression
    • Indications:
      • Together, they are the first drug in FDA trials specifically for suicidal bipolar depression
      • PTSD
    • Breakthrough Therapy Designation (BTD)
    • Expanded Access Protocol (EAP) — FDA‑authorized compassionate use
    • Phase 2/3 pivotal trials underway
      • Has begun the SPARC‑TMS pivotal trial, evaluating NRX‑101 + accelerated, neuro-navigated robotic TMS
      • Conducted in NRXP's HOPE clinics and military treatment facilities
  • HOPE Therapeutics
    • NRXP has acquired numerous neuropsychiatric clinics in Florida over the past 18 months
    • Partnered with Neurocare Group, gaining access to 400 TMS Clinics nationwide
      • Creates a nationwide “integrated neuroplastic therapy” platform
  • Major Hire Announcement - April 15, 2026
    • NRXP appoints Former Senior Defense Department Executive Dr. Dennis K. McBride, a career military medical scientist, to lead NRx Defense Systems
    • NRx is positioning NRX‑101 + robotic‑enabled TMS as a Defense Department–relevant technology for:
      • Military readiness
      • First responder resilience
      • Rapid treatment of depression, suicidality, and PTSD‑related conditions
u/stockratic — 13 days ago
▲ 7 r/10xPennyStocks+1 crossposts

(CYCU) Cycurion, Inc. Closes Acquisition of Digital Ally Video Solutions Business, Expanding Its Resources While Adding More Than $5 Million in Revenue and Over $1.2 Million in EBITDA — Bringing Annual Revenue Run Rate to Approximately $30 Million

Here's the PR that just landed:
Cycurion |

This company is making great headlines in the last week.

u/stockratic — 16 days ago
▲ 13 r/CAPR_Stock

July 29 Advisory Meeting: The evidence is clear. Anything other than a "Recommend Approval" decision would be unconscionable. Burn the Shorts!

reddit.com
u/stockratic — 27 days ago
▲ 3 r/10xPennyStocks+2 crossposts

Cycurion (CYCU)

CYCU is a cybersecurity company.

A victim of short selling and spoofing. They have a pending lawsuit against a large number of market makers and claim to have hard evidence to support their claims.

Everybody wants to find 5x to 10x return stocks. Here's a sleeper. Yesterday at $0.27 ($3M MC) and today ran to $0.44 so far and came back down to $.30. So, the word is getting out. I entered a comment on a YouTuber's penny-stock video page yesterday with some details about CYCU--asking him to make a video on CYCU. That video (on another stock) shows 2.5k views as of now, so maybe hundreds read my comment.

CYCU has a NASDAQ delisting notice, and they elected not to do a reverse split (had shareholder authority for a 1:7). The CEO and board felt they would be potentially shorted back down to under $1. They have asked NASDAQ for a hearing to get a short extension since they can no longer get 180-day extensions.

Latest acquisition has much higher profit margins and his 2026 revenue projection is $30M. That's right, $30M! And today started out with a $3.3M MC. Have cut debt about in half to around $4M and the new acquisition has margins as high as 65% to 70% (maybe double compared to their pre-existing business). The CEO predicts profitability by end of 2026 to Q1 2027.

Here's the 23-minute CEO (Kevin Kelly) interview published July 14: https://youtu.be/Bn45YsWdybU

My view is, I ultimately don't care if they have go to the OTC. I hope enough people watch the above video and choose to invest and keep it on the NASDAQ and get them over $1 for 10 consecutive days soon. But either way, there are so many companies on the OTC market that are doing very well -- for example, different business, but has anyone seen HGRAF (pre-revenue and over $1B valuation). If they have to move to OTC they can always relist on NASDAQ. It will have nothing to do with holding them back from reaching their 2026 revenue target. It will become a value story by end of the year.

I'm invested at $0.307. I'm holding this one for the 10x return (and potentially beyond). Not making the same mistake as when I bought DVLT at $.41, which ultimately hit $4, but I cashed out for only a double (I'll take it though!).

In my opinion, the stock should be well over $1 now. 5x (or $1.50) by end of 2026 to Q1 2027 is very realistic if annual revenue is anywhere close to $25M to $30M by end of 2026. Based on their projections at that point, meaning stability, profitability, and growth outlook given, then a gap up to 1x revenue (or $3) would make sense.

u/stockratic — 12 hours ago
▲ 10 r/CAPR_Stock

ETrade is showing over10,000 Aug 21 put options (and 96 call options) at $20 strike price. Just because there is an advisory meeting on July 29 does not mean it is a negative! May they get what's coming to them.

reddit.com
u/stockratic — 1 month ago